Although serum and tissue drug concentrations of anti-TNF agents reflect long-term sustained clinical remission in CD29, anti-infliximab antibody levels are increased in elderly patients with IBD despite their immunosenescence30. This evidence concerns the gene TNF and inflammatory bowel disease.